A Dried Blood Spot Analysis for Solithromycin in Adolescents, Children, and Infants: A Short Communication.

Published online

Journal Article

BACKGROUND: Solithromycin is a fourth-generation macrolide antibiotic with potential efficacy in pediatric community-acquired bacterial pneumonia. Pharmacokinetic (PK) studies of solithromycin in pediatric subjects are limited; therefore, application of minimally invasive drug sampling techniques, such as dried blood spots (DBS), may enhance the enrollment of children in PK studies. The objectives of this study were to compare solithromycin concentrations in DBS with those in liquid plasma samples (LPS) and to quantify the effects of modeling DBS concentrations on the results of a population PK model. METHODS: Comparability analysis was performed on matched DBS and LPS solithromycin concentrations collected from two different phase 1 clinical trials of solithromycin treatment in children (clinicaltrials.gov #NCT01966055 and #NCT02268279). Comparability of solithromycin concentrations was evaluated based on DBS:LPS ratio, median percentage prediction error (MPPE), and median absolute percentage prediction error (MAPE). The effect of correcting DBS concentrations for both hematocrit and protein binding was investigated. Additionally, a previously published population PK model (NONMEM) was leveraged to compare parameter estimates resulting from either DBS or LPS concentrations. RESULTS: A total of 672 paired DBS:LPS concentrations were available from 95 subjects (age: 0-17 years of age. The median (range) LPS and DBS solithromycin concentrations were 0.3 (0.01-12) µg/mL and 0.32 (0.01-14) µg/mL, respectively. MPPE and MAPE of raw DBS to LPS solithromycin concentrations were 5.26 and 22.95, respectively. Additionally, the majority of population PK parameter estimates resulting from modeling DBS concentrations were within 15% of those obtained from modeling LPS concentrations. CONCLUSION: Solithromycin concentrations in DBS were similar to those measured in LPS and did not require correction for hematocrit or protein binding.

Full Text

Duke Authors

Cited Authors

  • Beechinor, RJ; Cohen-Wolkowiez, M; Jasion, T; Hornik, CP; Lang, JE; Hernandez, R; Gonzalez, D

Published Date

  • July 15, 2019

Published In

PubMed ID

  • 31318840

Pubmed Central ID

  • 31318840

Electronic International Standard Serial Number (EISSN)

  • 1536-3694

Digital Object Identifier (DOI)

  • 10.1097/FTD.0000000000000670

Language

  • eng

Conference Location

  • United States